查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1736743

全球視神經疾病治療市場規模（按治療類型、神經系統疾病類型、最終用戶、區域範圍和預測）

Global Optic Nerve Disorders Treatment Market Size By Type of Treatment (Eye Drops, Steroids), By Type of Nerve Disorder (Glaucoma, Optic neuritis), By End User (Hospitals, Ophthalmology Clinics), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

視神經疾病治療市場規模及預測

2024 年視神經疾病治療市場規模價值 36 億美元，預計到 2032 年將達到 57 億美元，預測期內（2026-2032 年）的複合年成長率為 4.7%。

視神經疾病是指視神經（一組負責將視覺訊息從眼睛傳遞到大腦的神經纖維）因發炎（腫脹）而受損的疾病。視神經疾病的特徵是單眼暫時性視力喪失和眼球運動時不適。由於視神經疾病盛行率的上升、久坐生活方式的改變以及糖尿病、高血壓等文明病發病率的上升，預計全球視神經疾病治療市場在預測期內將持續成長。本研究報告對全球視神經疾病治療市場進行了全面評估。

定義視神經疾病治療的全球市場

連接視網膜細胞和視交叉的腦神經稱為視神經。視網膜的感光細胞捕捉光線，並透過視神經向大腦發送電脈衝。視神經功能障礙或損傷可能導致視力喪失，這取決於病變的類型和位置。視力問題可能發生在一隻眼睛或兩隻眼睛。電訊號從視網膜的感光細胞經由視神經傳送到大腦的視覺皮質。

視神經或其路徑的任何損傷都可能導致永久性眼損傷和視力喪失。視神經疾病是最常見的視神經損傷疾病之一。視神經因髓鞘（覆蓋視神經的保護膜）的損傷或缺失而發炎。研究人員表示，髓鞘的發炎和破壞可導致視神經疾病。視神經和視交叉在視交叉處交匯，扮演重要角色。

當視神經分裂成兩個部分時，兩側各有一半的神經纖維會交叉到另一側。神經損傷或神經保護膜的去除都會導致神經發炎。視神經疾病包括青光眼、視神經疾病、視神經萎縮症和視盤視網膜黃斑硬化症 (ODD)。治療方案包括皮質類固醇、靜脈注射免疫球蛋白 (IVIG)/血漿置換、維生素 B12 注射和手術，取決於疾病的程度和類型。

全球視神經疾病治療市場概況

根據世界衛生組織統計，2019年全球22億人視力受損或失明。其中，白內障、未矯正的屈光不正、青光眼和角膜混濁是視力受損的主要原因。青光眼是導致眼內壓升高和視神經疾病惡化的主要因素之一。青光眼也可能由感染疾病和化學性眼科疾病疾病引起，但它通常是遺傳性疾病。早期發現和早期治療的方法包括眼藥水、口服藥物和雷射治療。

多發性硬化症 (MS) 是一種自體免疫疾病，免疫系統會攻擊體內的健康細胞，是視神經疾病的主要原因。由於免疫力下降，MS 在高齡化社會中更為普遍，也可能由糖尿病、吸菸和感染疾病引起。由於久坐不動的生活方式、不良飲食和缺乏運動，糖尿病、高血壓和高血壓等文明病率呈上升趨勢，這使得 MS 更容易引起眼神經炎。因此，需要治療這種疾病的人數比例正在增加。類固醇通常用於治療視神經疾病並防止症狀惡化。

雖然視神經疾病尚無根治治療方法，但人們重視預防和早期發現，以避免藥物治療、藥物和手術帶來的併發症。老齡人口的成長以及人們日益意識到早期診斷以阻止症狀惡化的重要性，推動了對視神經疾病治療和手術的需求，從而支撐了此類治療市場的成長。然而，青光眼等視神經疾病治療的潛在副作用（例如眼睛顏色改變、眼窩凹陷、搔癢等）阻礙了市場的擴張。

目錄

第1章全球視神經疾病治療市集簡介

  • 市場概覽
  • 研究範圍
  • 先決條件

第 2 章 已驗證的市場研究調查方法

  • 資料探勘
  • 二次研究
  • 初步研究
  • 專家建議
  • 品質檢查
  • 最終審核
  • 數據三角測量
  • 自下而上的方法
  • 自上而下的方法
  • 調查流程
  • 資料來源

第3章執行摘要

  • 概述
  • 絕對的商機
  • 市場吸引力
  • 未來市場機會

第4章視神經疾病治療的全球市場展望

  • 概述
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
  • 波特五力模型
  • 價值鏈分析

第5章 全球視神經疾病治療市場（依治療類型）

  • 概述
  • 眼藥水
  • 類固醇
  • 靜脈注射免疫球蛋白/血漿置換
  • 維生素B12注射劑
  • 外科手術

第6章 全球視神經疾病治療市場（依神經系統疾病類型）

  • 概述
  • 青光眼
  • 視神經疾病
  • 其他

第7章全球視神經疾病治療市場（依最終使用者）

  • 概述
  • 醫院
  • 眼科診所
  • 門診手術中心

第8章全球視神經疾病治療市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 其他
    • 拉丁美洲
    • 中東和非洲

第9章全球視神經疾病治療市場的競爭格局

  • 概述
  • 各公司市場排名
  • 重點發展策略
  • 公司地理分佈
  • 公司在各行業的足跡
  • ACE矩陣

第10章 公司簡介

  • Bionure Farma SL
  • Teva Pharmaceutical Industries
  • Santen Pharmaceutical
  • Novartis AG
  • Pfizer
  • Allergan
  • Aerie Pharmaceuticals
  • Mallinckrodt Pharmaceuticals
  • Merck Sharp & Dohme Corp
  • Bausch Health Companies

第11章 重大進展

  • 產品發布/開發
  • 合併與收購
  • 業務擴展
  • 夥伴關係與合作

第12章 附錄

  • 相關調查
簡介目錄
Product Code: 40550

Optic Nerve Disorders Treatment Market Size And Forecast

Optic Nerve Disorders Treatment Market size was valued at USD 3.6 Billion in 2024 and is projected to reach USD 5.7 Billion by 2032, growing at a CAGR of 4.7% during the forecast period 2026-2032.

Optic neuritis is a condition in which the optic nerve, a group of nerve fibers that transmits visual information from the eye to the brain, is destroyed by inflammation (swelling). Optic neuritis is characterized by temporary vision loss in one eye and discomfort with eye movement. Due to the rising prevalence of optic illnesses, the adoption of a sedentary lifestyle, and the rising incidence of lifestyle diseases like diabetes, Blood Pressure & Hypertension, the global market for treatments for optic nerve disorders is anticipated to grow over the course of the forecasted period. The market is comprehensively evaluated in the study on the global market for treating optic nerve disorders.

Global Optic Nerve Disorders Treatment Market Definition

The cranial nerves that connect the retinal cells to the optic chiasm are known as the optic nerves. The retina's photoreceptor cells take in light and send electric impulses to the brain through the optic nerves. Loss of vision could result from malfunction or damage to the optic nerves, depending on the type and location of the lesion. One or both eyes could experience vision impairment. Electrical signals are sent from retinal photoreceptor cells via the optic nerve to the brain's visual cortex.

Any damage to the optic nerve or its pathways has the potential to permanently harm the eyes and cause vision loss. One of the most frequent conditions that might harm the optic nerve is optic neuritis. The optic nerve is inflamed as a result of damage to or loss of myelin, the protective covering that covers it. Optic neuritis may be brought on by inflammation and myelin breakdown, according to researchers. The two nerves perform an essential task and converge at the optic chiasm.

Half of each side's nerve fibers cross over to the other side as the optic nerve splits in half. Injury and the removal of the nerve's protective covering both cause inflammation of the nerve. Glaucoma, optic neuritis, atrophy of the optic nerve, and optic disc drusen (ODD), among other conditions, are optic nerve disorders. Therapy options include corticosteroids, intravenous immune globulin (IVIG)/plasma exchange, vitamin B12 injection, and surgery, among others, depending on the degree and kind of disease identified.

Global Optic Nerve Disorders Treatment Market Overview

In 2019, 2.2 billion individuals worldwide experienced visual impairment or blindness, according to WHO. Out of these, cataracts, uncorrected refractive errors, glaucoma, corneal opacification, etc. are the main causes of vision impairment. One significant factor that contributes to the increase in fluid pressure in the eye, which worsens optic nerve damage, is glaucoma. It is frequently inherited by people, although it can also be brought on by an infection, an eye injury from chemicals, etc. Early detection and treatment options include eye drops, oral drugs, and operations like laser therapy.

Multiple sclerosis (MS), an autoimmune condition associated with the immune system attacking the body's healthy cells, is the primary cause of optic neuritis. Due to lowered immunity, MS is becoming more common in the aging population, while it can also be brought on by diabetes, smoking, infections, etc. Due to sedentary lifestyles, bad diets, lack of physical activity, etc., there is an increase in lifestyle disorders like diabetes, blood pressure, hypertension, etc., which further increases the likelihood that MS may cause ocular neuritis. The percentage of persons who need therapy for the disease is increasing as a result. Steroids are typically used to treat optic neuritis in order to prevent the condition's future progression.

Although there is no definitive cure for optic nerve illnesses, there is a lot of emphasis on preventing them and finding them early to avoid complications from medication, medications, and surgery. The increase in the elderly population and the growing awareness of the need for early diagnosis to stop the condition from getting worse has increased the demand for drugs and surgeries for treating optic nerve disorders, which has fueled the growth of the market for those treatments. However, the market's expansion is being hampered by potential side effects associated with the usage of medications for the treatment of optic nerve disorders like glaucoma, such as changing eye color, sunken eyes, itching, etc.

Global Optic Nerve Disorders Treatment Market Segmentation Analysis

The Global Optic Nerve Disorders Treatment Market is segmented on the basis of Type of Treatment, Type of Nerve Disorder, End User, And Geography.

Optic Nerve Disorders Treatment Market, By Type of Treatment

  • Eye Drops
  • Steroids
  • Intravenous immune Globulin/ Plasma Exchange
  • Vitamin B12 injection
  • Surgery

Based on Type of Treatment, The market is segmented into Eye Drops, Steroids, Intravenous immune globulin (IVIG)/Plasma Exchange, Vitamin B12 injection, and Surgery. Due to their simplicity of use, quick start of the action, and increased efficacy, eye drops are predicted to experience the largest growth during the estimated period.

  • Numerous common disorders are treated using eye drops. They can be used for tired, itchy eyes brought on by allergies. They might be recommended for bacterial or viral infections as well as other disorders like glaucoma. The entire therapeutic benefit of the drug might not be experienced when eye drops are not properly administered or used.

Optic Nerve Disorders Treatment Market, By Type of Nerve Disorder

  • Glaucoma
  • Optic neuritis
  • Others

Based on Type of Nerve Disorder, The market is segmented into Glaucoma, Optic neuritis, and Others. Due to a lack of knowledge about glaucoma and the rising elderly population, glaucoma is anticipated to rise the most during the anticipated time. due to an increase in open-angle glaucoma prevalence. Additionally, it is projected that an increase in the number of medications approved for the treatment of open-angle glaucoma will spur market expansion.

  • Additionally, the market for treatments for optic neuritis is anticipated to increase at the quickest rate throughout the anticipated period. This is ascribed to the rise in optic neuritis prevalence, the availability of reimbursement policies, and rising public awareness of multiple sclerosis driving the market expansion.

Optic Nerve Disorders Treatment Market, By End User

  • Hospitals
  • Ophthalmology Clinics
  • Ambulatory Surgical Centers

Based on End User, The market is segmented into Hospitals, Ophthalmology Clinics, and Ambulatory Surgical Centers. Due to the increased prevalence of optical disorders, accessibility to cutting-edge technology, and well-established healthcare infrastructure, the hospital segment is anticipated to grow the most throughout the anticipated period.

  • The availability of enhanced healthcare infrastructure, the rise in unmet healthcare needs, the rise in the prevalence of eye disease, and the spike in demand for medications to treat optic nerve disorders all point to high promise in unexplored, emerging markets. Additionally, the desire for better healthcare services, large government investments in enhancing the infrastructure for healthcare, and the growth of the medical tourism sector in emerging nations are all contributing to the significant growth of the healthcare sector in emerging economies.

Optic Nerve Disorders Treatment Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America

Based on Geography, The Global Optic Nerve Disorders Treatment Market is classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. Due to its high illness prevalence, accessibility of reimbursement policies, and rising public awareness of multiple sclerosis and optic neuritis, the Asia Pacific area is anticipated to rise more than any other region throughout the forecasted period.

  • The market has grown in this area due to the presence of pharmaceutical companies there as well as the increasing purchasing power of populous countries like China and India. The market is expanding due to the aging population as well as the rising prevalence of diseases affecting the optic nerve, including glaucoma and optic neuritis.

Key Players

The "Global Optic Nerve Disorders Treatment Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as Bionure Farma S.L., Teva Pharmaceutical Industries Ltd, Santen Pharmaceutical Co. Ltd., Novartis AG, Pfizer Inc., Allergan plc., Aerie Pharmaceuticals Inc, Mallinckrodt Pharmaceuticals, Merck Sharp & Dohme Corp, and Bausch Health Companies, Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

Key Developments

  • In February 2022, The results of a recent trial conducted by Horizon Therapeutics plc (Nasdaq: HZNP) showed that UPLIZNA medication effectively reduced the intensity of attacks in NMOSD patients.
  • Ace Matrix Analysis
  • The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.
  • Market Attractiveness
  • The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Optic Nerve Disorders Treatment Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.
  • Porter's Five Forces
  • The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. The porter's five forces model can be used to assess the competitive landscape in Global Optic Nerve Disorders Treatment Market gauge the attractiveness of a certain sector, and assess investment possibilities.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 2.1 Data mining
  • 2.2 Secondary research
  • 2.3 Primary research
  • 2.4 Subject matter expert advice
  • 2.5 Quality check
  • 2.6 Final review
  • 2.7 Data triangulation
  • 2.8 Bottom-up approach
  • 2.9 Top-down approach
  • 2.10 Research flow
  • 2.11 Data sources

3 EXECUTIVE SUMMARY

  • 3.1 Overview
  • 3.2 Absolute $ Opportunity
  • 3.3 Market attractiveness
  • 3.4 Future Market Opportunities

4 GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET, BY TYPE OF TREATMENT

  • 5.1 Overview
  • 5.2 Eye Drops
  • 5.3 Steroids
  • 5.4 Intravenous immune Globulin/ Plasma Exchange
  • 5.5 Vitamin B12 injection
  • 5.6 Surgery

6 GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET, BY TYPE OF NREVE DISORDER

  • 6.1 Overview
  • 6.2 Glaucoma
  • 6.3 Optic neuritis
  • 6.4 Others

7 GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET, BY END USER

  • 7.1 Overview
  • 7.2 Hospitals
  • 7.3 Ophthalmology Clinics
  • 7.4 Ambulatory Surgical Centers

8 GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East and Africa

9 GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies
  • 9.4 Company Regional Footprint
  • 9.5 Company Industry Footprint
  • 9.6 ACE Matrix

10 COMPANY PROFILES

  • 10.1 Bionure Farma S.L.
    • 10.1.1 Company Overview
    • 10.1.2 Company Insights
    • 10.1.3 Business Breakdown
    • 10.1.4 Product Benchmarking
    • 10.1.5 Key Developments
    • 10.1.6 Winning Imperatives
    • 10.1.7 Current Focus & Strategies
    • 10.1.8 Threat from Competition
    • 10.1.9 SWOT Analysis
  • 10.2 Teva Pharmaceutical Industries
    • 10.2.1 Company Overview
    • 10.2.2 Company Insights
    • 10.2.3 Business Breakdown
    • 10.2.4 Product Benchmarking
    • 10.2.5 Key Developments
    • 10.2.6 Winning Imperatives
    • 10.2.7 Current Focus & Strategies
    • 10.2.8 Threat from Competition
    • 10.2.9 SWOT Analysis
  • 10.3 Santen Pharmaceutical
    • 10.3.1 Company Overview
    • 10.3.2 Company Insights
    • 10.3.3 Business Breakdown
    • 10.3.4 Product Benchmarking
    • 10.3.5 Key Developments
    • 10.3.6 Winning Imperatives
    • 10.3.7 Current Focus & Strategies
    • 10.3.8 Threat from Competition
    • 10.3.9 SWOT Analysis
  • 10.4 Novartis AG
    • 10.4.1 Company Overview
    • 10.4.2 Company Insights
    • 10.4.3 Business Breakdown
    • 10.4.4 Product Benchmarking
    • 10.4.5 Key Developments
    • 10.4.6 Winning Imperatives
    • 10.4.7 Current Focus & Strategies
    • 10.4.8 Threat from Competition
    • 10.4.9 SWOT Analysis
  • 10.5 Pfizer
    • 10.5.1 Company Overview
    • 10.5.2 Company Insights
    • 10.5.3 Business Breakdown
    • 10.5.4 Product Benchmarking
    • 10.5.5 Key Developments
    • 10.5.6 Winning Imperatives
    • 10.5.7 Current Focus & Strategies
    • 10.5.8 Threat from Competition
    • 10.5.9 SWOT Analysis
  • 10.6 Allergan
    • 10.6.1 Company Overview
    • 10.6.2 Company Insights
    • 10.6.3 Business Breakdown
    • 10.6.4 Product Benchmarking
    • 10.6.5 Key Developments
    • 10.6.6 Winning Imperatives
    • 10.6.7 Current Focus & Strategies
    • 10.6.8 Threat from Competition
    • 10.6.9 SWOT Analysis
  • 10.7 Aerie Pharmaceuticals
    • 10.7.1 Company Overview
    • 10.7.2 Company Insights
    • 10.7.3 Business Breakdown
    • 10.7.4 Product Benchmarking
    • 10.7.5 Key Developments
    • 10.7.6 Winning Imperatives
    • 10.7.7 Current Focus & Strategies
    • 10.7.8 Threat from Competition
    • 10.7.9 SWOT Analysis
  • 10.8 Mallinckrodt Pharmaceuticals
    • 10.8.1 Company Overview
    • 10.8.2 Company Insights
    • 10.8.3 Business Breakdown
    • 10.8.4 Product Benchmarking
    • 10.8.5 Key Developments
    • 10.8.6 Winning Imperatives
    • 10.8.7 Current Focus & Strategies
    • 10.8.8 Threat from Competition
    • 10.8.9 SWOT Analysis
  • 10.9 Merck Sharp & Dohme Corp
    • 10.9.1 Company Overview
    • 10.9.2 Company Insights
    • 10.9.3 Business Breakdown
    • 10.9.4 Product Benchmarking
    • 10.9.5 Key Developments
    • 10.9.6 Winning Imperatives
    • 10.9.7 Current Focus & Strategies
    • 10.9.8 Threat from Competition
    • 10.9.9 SWOT Analysis
  • 10.10 Bausch Health Companies
    • 10.10.1 Company Overview
    • 10.10.2 Company Insights
    • 10.10.3 Business Breakdown
    • 10.10.4 Product Benchmarking
    • 10.10.5 Key Developments
    • 10.10.6 Winning Imperatives
    • 10.10.7 Current Focus & Strategies
    • 10.10.8 Threat from Competition
    • 10.10.9 SWOT Analysis

11 KEY DEVELOPMENTS

  • 11.1 Product Launches/Developments
  • 11.2 Mergers and Acquisitions
  • 11.3 Business Expansions
  • 11.4 Partnerships and Collaborations

12 APPENDIX

  • 12.1 Related Research